35 related articles for article (PubMed ID: 36195287)
1. A CXCR3-Activating Peptide Increases Tear Break Up Time and Corrects Corneal haze in a Rabbit Model of Environmental Dry Eye.
Wells A; Wang Y; Shao H; Sohnen P; Swamynathan SK
J Pharm Pharmacol Res; 2024; 8(2):23-27. PubMed ID: 38736523
[TBL] [Abstract][Full Text] [Related]
2. ELR-negative CXC chemokine CXCL11 (IP-9/I-TAC) facilitates dermal and epidermal maturation during wound repair.
Yates CC; Whaley D; Y-Chen A; Kulesekaran P; Hebda PA; Wells A
Am J Pathol; 2008 Sep; 173(3):643-52. PubMed ID: 18669615
[TBL] [Abstract][Full Text] [Related]
3. Delayed and deficient dermal maturation in mice lacking the CXCR3 ELR-negative CXC chemokine receptor.
Yates CC; Whaley D; Kulasekeran P; Hancock WW; Lu B; Bodnar R; Newsome J; Hebda PA; Wells A
Am J Pathol; 2007 Aug; 171(2):484-95. PubMed ID: 17600132
[TBL] [Abstract][Full Text] [Related]
4. Delayed reepithelialization and basement membrane regeneration after wounding in mice lacking CXCR3.
Yates CC; Whaley D; Hooda S; Hebda PA; Bodnar RJ; Wells A
Wound Repair Regen; 2009; 17(1):34-41. PubMed ID: 19152649
[TBL] [Abstract][Full Text] [Related]
5. CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways.
Berchiche YA; Sakmar TP
Mol Pharmacol; 2016 Oct; 90(4):483-95. PubMed ID: 27512119
[TBL] [Abstract][Full Text] [Related]
6. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
[TBL] [Abstract][Full Text] [Related]
7. Role of CXCR3 in fibrotic tissue responses.
Wells A
Int J Biochem Cell Biol; 2022 Nov; 152():106311. PubMed ID: 36195287
[TBL] [Abstract][Full Text] [Related]
8. The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment.
Reynders N; Abboud D; Baragli A; Noman MZ; Rogister B; Niclou SP; Heveker N; Janji B; Hanson J; Szpakowska M; Chevigné A
Cells; 2019 Jun; 8(6):. PubMed ID: 31216755
[TBL] [Abstract][Full Text] [Related]
9. Skin wound healing and scarring: fetal wounds and regenerative restitution.
Yates CC; Hebda P; Wells A
Birth Defects Res C Embryo Today; 2012 Dec; 96(4):325-33. PubMed ID: 24203921
[TBL] [Abstract][Full Text] [Related]
10. CXCR3-binding chemokines: novel multifunctional therapeutic targets.
Lazzeri E; Romagnani P
Curr Drug Targets Immune Endocr Metabol Disord; 2005 Mar; 5(1):109-18. PubMed ID: 15777209
[TBL] [Abstract][Full Text] [Related]
11. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
Karin N
Front Immunol; 2020; 11():976. PubMed ID: 32547545
[TBL] [Abstract][Full Text] [Related]
12. Targeting Fibrotic Signaling: A Review of Current Literature and Identification of Future Therapeutic Targets to Improve Wound Healing.
Hetzler PT; Dash BC; Guo S; Hsia HC
Ann Plast Surg; 2019 Dec; 83(6):e92-e95. PubMed ID: 31246672
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
